Karuna Therapeutics, Inc. with ticker code (KRTX) have now 19 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $320.00 and $197.00 suggesting an average Analsyt target price of $265.26. Now with the previous closing price of $208.00 this is indicating there is a potential upside of 27.5%. The 50 day moving average now sits at $176.41 while the 200 day moving average is $193.39. The company has a market capitalization of 7.88B. The stock price is currently at: $208.80 USD
The potential market cap would be $10,045,980,915 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of -, revenue per share of $0.16 and a -21.51% return on assets.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The Company is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.
